Head-to-head · WeighScore
Embody vs Rewinding RX
The verdict
Embody takes it — 76.2/100 to 59.5/100.
Embody grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Embody offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Embody | Rewinding RX |
|---|---|---|
| WeighScore | 76.2/100 | 59.5/100 |
| Grade | C | C |
| Scorecard rank | #52 | #340 |
| Semaglutide | $79/mo (all doses, promotional rate, compounded) | Not disclosed |
| Tirzepatide | $129/mo (all doses, promotional rate, compounded) | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #52 · C
Strengths
- Among the lowest flat rates in the compounded segment — $79/mo semaglutide and $129/mo tirzepatide injection at every dose
- Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
- Available in all 50 states with no insurance friction
- 24/7 unlimited clinician messaging and dose-adjustment support included
- Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine
Where it loses points
- The $79 flat rate relies on an auto-applied promo 'locked forever' — list price in the terms is $199/mo and reviewers allege the lock isn't honored
- Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
- Pharmacy partners not publicly named — compounding source transparency is limited
- Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
Graded #340 · C
Strengths
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer — uncommon transparency
- MD-only physician network ('never a physician assistant or nurse')
- All-50-state coverage with physician state-licensing matching
- Corporate entity disclosed (Rewinding RX Ltd.)
Where it loses points
- Pricing not shown — fully gated behind sign-up
- Pharmacy partner not named (only generic 503A/503B references)
- Medical director / clinical leadership not disclosed
- Governing law, arbitration venue, and corporate address not disclosed
- Tirzepatide not listed on the homepage (semaglutide only confirmed)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.